Publications by authors named "Garcia-Villanueva M"
Article Synopsis
- Diffuse alveolar hemorrhage (DAH) is a severe and uncommon complication in systemic lupus erythematosus (SLE) patients, with early diagnosis and treatment critical for improving survival rates.
- In a study from the RELESSER register, 37 out of 4024 SLE patients experienced DAH, with notable characteristics including a high prevalence of women and links to renal issues and thrombocytopenia.
- Factors associated with higher mortality in DAH patients included smoking, prior lupus nephritis, infections, and the use of cyclophosphamide, with a mortality rate of 35.7% observed in the cohort.
Objective: To assess organ damage, with emphasis on the cardiovascular system, over the different stages of the disease in a large SLE cohort.
Methods: Multicentre, longitudinal study of a cohort of 4219 patients with SLE enrolled in the Spanish Society of Rheumatology Lupus Registry. Organ damage was ascertained using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI).
Objectives: The aims of this study were to investigate the prevalence of dose reduction in patients with SLE treated with belimumab (BEL) in Spain, analyze treatment modalities, and determine impact on control of disease activity.
Methods: Retrospective longitudinal and multicentre study of SLE patients treated with BEL. Data on disease activity, treatments and outcomes were recorded before and after reduction (6-12 months), and they were compared.
Objective: To develop an improved score for prediction of severe infection in patients with systemic lupus erythematosus (SLE), namely, the SLE Severe Infection Score-Revised (SLESIS-R) and to validate it in a large multicentre lupus cohort.
Methods: We used data from the prospective phase of RELESSER (RELESSER-PROS), the SLE register of the Spanish Society of Rheumatology. A multivariable logistic model was constructed taking into account the variables already forming the SLESIS score, plus all other potential predictors identified in a literature review.
Objectives: To provide an overview on the current use of belimumab (BLM) in SLE patients in clinical practice and to examine its efficacy in terms of standardized outcomes, drug survival, as well as patient and safety profiles.
Methods: A longitudinal retrospective multicenter cohort including SLE patients treated with BLM at 18 Spanish centers. Data was collected upon initiation of BLM, at 6 and 12 months after initiation, and at the last recorded visit.
Acute myocardial infarction (AMI) is associated with systemic inflammatory processes and metabolic alterations. Microbial-derived metabolites, such as short-chain fatty acids and trimethylamine N-oxide (TMAO), have emerged in recent years as key players in the modulation of inflammation, with potential implications for cardiovascular diseases. We performed a prospective observational study that monitored the serological concentration of bacterial metabolites in 45 young patients (<55 years) without cardiovascular risk factors but with AMI, at hospital admission and at 3 months of follow-up, and compared them with a control group.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to analyze the diagnostic methods for giant cell arteritis (GCA) in clinical practice and the impact of EULAR recommendations on these methods.
- A retrospective analysis included 1,675 GCA patients across 26 hospitals in Spain, finding that temporal artery biopsy (TAB) was initially the most common diagnostic test but usage declined over time.
- Imaging techniques, particularly ultrasound, significantly increased in use from 2013 to 2019, suggesting a shift in preference for non-invasive diagnostic methods influenced by recent guidelines.
Objectives: To evaluate the properties of a single question to determine patient perception of remission and disease activity; to compare this with existing definitions for remission and low disease activity (LDA).
Methods: Single-center, cross-sectional study in a tertiary care hospital. Patients with axSpA (fulfilling ASAS criteria) were consecutively included.
Article Synopsis
- The study analyzed how common major central nervous system issues are in patients with systemic lupus erythematosus (SLE) and their impact on survival and mortality.
- Out of 3,591 SLE patients, 11.5% experienced significant CNS neuropsychiatric problems, leading to higher annual mortality rates, particularly from cerebrovascular disease and organic brain syndrome.
- The findings indicate that major CNS complications significantly increase mortality risk, with specific issues like CVD and organic brain syndrome having the worst survival outcomes.
Article Synopsis
- The study aims to evaluate how different targeted therapies and other factors impact COVID-19 hospitalisation risk in patients with inflammatory rheumatic diseases.
- A cohort of 7,782 patients was analyzed, revealing that while most targeted therapies weren't linked to increased hospitalisation risk, TNF inhibitors significantly lowered it, while rituximab appeared to increase risk.
- Key demographics and comorbidities, alongside COVID-19 symptoms, also influenced hospitalisation likelihood, indicating that multiple factors play a role in patient outcomes.
Objective: To describe the cohort of patients with inflammatory rheumatic diseases (IRD) hospitalized due to SARS-CoV-2 infection in the Ramón y Cajal Hospital, and to determine the increased risk of severe coronavirus disease 2019 (COVID-19) in patients with no IRD.
Methods: This is a retrospective single-center observational study of patients with IRD actively monitored in the Department of Rheumatology who were hospitalized due to COVID-19.
Results: Forty-one (1.
Objectives: This article estimates the frequency of polyautoimmunity and associated factors in a large retrospective cohort of patients with SLE.
Methods: RELESSER (Spanish Society of Rheumatology Lupus Registry) is a nationwide multicentre, hospital-based registry of SLE patients. This is a cross-sectional study.
Article Synopsis
- - MAP kinase interacting kinases (MNKs), specifically the MNK1b isoform, play a crucial role in cancer development by phosphorylating the eukaryotic initiation factor 4E (eIF4E), which is important for oncogenic transformation
- - In a study of 69 breast tumor samples, both MNK1 isoforms (MNK1a and MNK1b) showed significantly increased expression in tumors compared to adjacent normal tissue, with MNK1b overexpressed primarily in triple-negative breast cancers
- - High levels of MNK1b are linked to poorer survival rates and may serve as a potential therapeutic target for treatment, especially in aggressive triple-negative breast cancer cases
Objectives: To analyse the quality of life (QoL) of persons over 60 years of age in Bizkaia (Basque Country, Spain), not institutionalised and without cognitive impairment, and the relation and possible influence of the perception of the state of health with the cognitive level and the activities that they carry out.
Subjects And Methods: Evaluation of a sample of 317 persons that belong to a longitudinal study. In 269 cases, there was a reliable informant.
Objective: Different lines of evidence have highlighted the role of IL-17A in the inflammatory process occurring in giant cell arteritis (GCA). The aim of the present study was to assess whether the IL17A locus influences GCA susceptibility and its clinical subphenotypes.
Methods: We carried out a large meta-analysis including a total of 1266 biopsy-proven GCA patients and 3779 healthy controls from four European populations (Spain, Italy, Germany and Norway).
Objectives: The Xq28 region, containing IRAK and MECP2, represent a common susceptibility locus for a high number of autoimmune diseases. Our aim in the present study was to evaluate the influence of the IRAK1 and MECP2 autoimmunity-associated genetic variants in the giant cell arteritis (GCA) susceptibility and its clinical subphenotypes.
Methods: We analysed a total of 627 female biopsy-proven GCA patients and 1,520 female healthy controls of Spanish Caucasian origin.
Neonatal hypoxic-ischemic encephalopathy (HIE) causes high mortality and long-term morbidity rates. The magnitude of the neuronal damage depends on the duration and severity of the initial insult combined with the deleterious effects of reperfusion and apoptosis. Currently, a diagnosis of HIE is based largely on the neurological and histological findings.
View Article and Find Full Text PDFObjective: To analyse the role of the PTPN22 and CSK genes, previously associated with autoimmunity, in the predisposition and clinical phenotypes of giant cell arteritis (GCA).
Methods: Our study population was composed of 911 patients diagnosed with biopsy-proven GCA and 8136 unaffected controls from a Spanish discovery cohort and three additional independent replication cohorts from Germany, Norway and the UK. Two functional PTPN22 polymorphisms (rs2476601/R620W and rs33996649/R263Q) and two variants of the CSK gene (rs1378942 and rs34933034) were genotyped using predesigned TaqMan assays.
Amyloidosis is an uncommon syndrome consisting of a number of disorders having in common an extracellular deposit of fibrillary proteins. This results in functional and structural changes in the affected organs, depending on deposit location and severity. Amyloid infiltration of the thyroid gland may occur in 50% and up to 80% of patients with primary and secondary amyloidosis respectively.
View Article and Find Full Text PDFBackground: Recent findings support the important role of antibodies in multiple sclerosis (MS) physiopathology. Thus, local IgG synthesis is a hallmark of the disease, and intrathecal IgM synthesis associates with a poor disease outcome.
Methodology: The aim of this study was to investigate the presence of IgM and IgG in demyelinating lesions using high sensitivity immunohistochemistry techniques in necropsies from fourteen MS patients, four controls without neurological disease and four cases with non MS CNS inflammatory disease.
Glucocorticoids, aspirin, conventional antimalarials and immunosuppressants are the mainstay of treatment of Systemic Lupus Erythematosus (SLE). Until recently, the first three were the only agents approved for treatment. A better understanding of the pathophysiology of the immune system has identified new therapeutic targets.
View Article and Find Full Text PDFGlucocorticoids, aspirin, antimalarials and conventional immunosuppressants are the mainstay of treatment of Systemic Lupus Erythematosus (SLE). Until recently, the first three were the only agents approved for treatment. A better understanding of the pathophysiology of the immune system has identified new therapeutic targets.
View Article and Find Full Text PDF